Final Results of a Phase 2, Open-Label Study of Indisulam, Idarubicin and Cytarabine in Patients with Relapsed or Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

BACKGROUND: Indisulam possesses anticancer properties through down-regulation of various cell cycle checkpoint molecules, thereby blocking the phosphorylation of retinoblastoma protein and inducing p53 and p21. Indisulam exhibits synergy with nucleoside analogs and topoisomerase inhibitors. METHODS:...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Assi, Rita, Kantarjian, Hagop, Kadia, Tapan M., Pemmaraju, Naveen, Jabbour, Elias, Jain, Nitin, Daver, Naval, Estrov, Zeev, Uehara, Taisuke, Owa, Takashi, Cortes, Jorge E., Borthakur, Gautam
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6800041/
https://ncbi.nlm.nih.gov/pubmed/29660836
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.31398
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados